Global Pernicious Anemia Diagnosis And Treatment Market To Reach $1.97 Billion By 2029 With A Growth Rate Of 6.8%

June 19, 2025 09:45 PM AEST | By EIN Presswire
 Global Pernicious Anemia Diagnosis And Treatment Market To Reach $1.97 Billion By 2029 With A Growth Rate Of 6.8%
Image source: EIN Presswire

LONDON, GREATER LONDON, UNITED KINGDOM, June 19, 2025 /EINPresswire.com/ -- A noticeable surge in the pernicious anemia diagnosis and treatment market size over recent years is reported. Growth from $1.42 billion in 2024 to $1.52 billion in 2025 was observed, recording a compound annual growth rate CAGR of 7.0%. Factors contributing to this increase include the escalating awareness around vitamin B12 deficiency, the rise in autoimmune disorders, a growing geriatric population, enhanced physician education on anemia, and the accessibility of oral and injectable vitamin B12.

What Is The Projected Future Growth Of The Pernicious Anemia Diagnosis And Treatment Market Size?
The upcoming years predict robust growth in the pernicious anemia diagnosis and treatment market. It is projected to reach $1.97 billion in 2029 at a compound annual growth rate CAGR of 6.8%. The anticipated expansion can be linked to the advancement of telemedicine services, increasing demand for early diagnosis, a rising focus on personalized medicine, government screening initiatives, and a preference for non-invasive treatments among patients. Key trends of the forecast period include long-acting vitamin B12 formulations, a growing use of home-based diagnostic kits, integration of artificial intelligence AI in anemia detection, advancements in digital health monitoring tools, and diagnostic technologies.

Get Your Free Sample Market Report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=24360&type=smp

What Are The Key Drivers Propelling The Growth Of The Pernicious Anemia Diagnosis And Treatment Market?
The surge in cases of vitamin B12 deficiency is anticipated to boost the market growth. Vitamin B12 deficiency impairs red blood cell production, causing symptoms including fatigue, weakness, and neurological issues. The rise in this deficiency can be attributed to an increased adoption of plant-based diets that often lack sufficient natural sources of B12 and can lead to inadequate intake without proper supplementation. This deficiency supports the necessity for pernicious anemia diagnosis and treatment. For instance, according to the National Health Service NHS, a UK-based government health organization, in February 2023, both vitamin B12 and folate deficiencies were more prevalent in older adults – roughly 1 in 10 individuals 75 years of age or older, and 1 in 20 of those 65 to 74 years of age. Consequently, the rising prevalence of vitamin B12 deficiency is a significant driver for growth in the pernicious anemia diagnosis and treatment market.

What Key Player Strategies Are Driving The Pernicious Anemia Diagnosis And Treatment Market?
Industry giants in the pernicious anemia diagnosis and treatment market include Pfizer Inc., F.Hoffmann-La Roche Ltd., AbbVie Inc., Bayer AG, Novartis AG, Sanofi S.A., Bristol Myers Squibb Company, Thermo Fisher Scientific Inc., GSK plc, Takeda Pharmaceutical Company Limited, Lupin Limited, Eli Lilly and Company, Amgen Inc., DSM Nutritional Products AG, Bio-Rad Laboratories Inc., CSL Vifor Pharma, Daiichi Sankyo Co. Ltd., Par Pharmaceutical Companies Inc., AdvaCare Pharma, Monobind Inc.

Order Your Report Now For A Swift Delivery:
https://www.thebusinessresearchcompany.com/report/pernicious-anemia-diagnosis-and-treatment-global-market-report

What Are The Emerging Trends In The Pernicious Anemia Diagnosis And Treatment Market?
Players in this market are cultivating innovative solutions such as vitamin B12 maintenance therapy solutions to augment patient adherence and long-term disease management. A recent development in February 2024 saw India-based pharmaceutical company, Lupin Pharmaceuticals Inc., launch a cyanocobalamin nasal spray, 500 mcg/spray - a non-invasive alternative for vitamin B12 supplementation. This revolutionary nasal spray improves B12 absorption and supports the effective management of vitamin B12 deficiency, enhancing patient compliance and treatment outcomes.

How Is The Pernicious Anemia Diagnosis And Treatment Market Segmented?
Notably, the pernicious anemia diagnosis and treatment market is stratified by various factors:
By Type: Complete Blood Count Test, Vitamin B12 Deficiency test, Intrinsic Factor Deficiency Test
By Treatment: Vitamin B12 Injections, Vitamin B12 Pills, Spray
By Route Of Administration: Injection, Oral, Intranasal
By End-User: Hospitals, Clinics, Diagnostic Centres, Other End-users

Sub segments include:
By Complete Blood Count CBC Test: Red Blood Cell Count, Hemoglobin Concentration, Hematocrit Levels, Mean Corpuscular Volume MCV, White Blood Cell Count, Platelet Count

What Are The Regional Insights In The Pernicious Anemia Diagnosis And Treatment Market?
Historically, North America was the largest region in the pernicious anemia diagnosis and treatment market in 2024. Other regions covered in the report include Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Browse Through More Similar Reports By The Business Research Company:

Blood And Blood Components Global Market Report 2025
http://thebusinessresearchcompany.com/report/blood-and-blood-components-global-market-report

Blood Cancer Drugs Global Market Report 2025
https://www.thebusinessresearchcompany.com/report/blood-cancer-drugs-global-market-report

Blood Collection Devices Global Market Report 2025
https://www.thebusinessresearchcompany.com/report/blood-collection-devices-global-market-report

About The Business Research Company
Learn More About The Business Research Company. With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Contact us at:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 3156230293
Asia +44 2071930708
Europe +44 2071930708
Email us at [email protected]

Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Oliver Guirdham
The Business Research Company
+44 20 7193 0708
[email protected]

Legal Disclaimer:

EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.


Disclaimer

The content, including but not limited to any articles, news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations and video (Content) is a service of Kalkine Media Pty Ltd (“Kalkine Media, we or us”), ACN 629 651 672 and is available for personal and non-commercial use only. The principal purpose of the Content is to educate and inform. The Content does not contain or imply any recommendation or opinion intended to influence your financial decisions and must not be relied upon by you as such. Some of the Content on this website may be sponsored/non-sponsored, as applicable, but is NOT a solicitation or recommendation to buy, sell or hold the stocks of the company(s) or engage in any investment activity under discussion. Kalkine Media is neither licensed nor qualified to provide investment advice through this platform. Users should make their own enquiries about any investments and Kalkine Media strongly suggests the users to seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice), as necessary.
The content published on Kalkine Media also includes feeds sourced from third-party providers. Kalkine does not assert any ownership rights over the content provided by these third-party sources. The inclusion of such feeds on the Website is for informational purposes only. Kalkine does not guarantee the accuracy, completeness, or reliability of the content obtained from third-party feeds. Furthermore, Kalkine Media shall not be held liable for any errors, omissions, or inaccuracies in the content obtained from third-party feeds, nor for any damages or losses arising from the use of such content.
Kalkine Media hereby disclaims any and all the liabilities to any user for any direct, indirect, implied, punitive, special, incidental or other consequential damages arising from any use of the Content on this website, which is provided without warranties. The views expressed in the Content by the guests, if any, are their own and do not necessarily represent the views or opinions of Kalkine Media. Some of the images/music that may be used on this website are copyrighted to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures displayed/music used on this website unless stated otherwise. The images/music that may be used on this website are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have made reasonable efforts to accredit the source wherever it was indicated as or found to be necessary.
This disclaimer is subject to change without notice. Users are advised to review this disclaimer periodically for any updates or modifications.


AU_advertise

Advertise your brand on Kalkine Media

Sponsored Articles


Investing Ideas

Previous Next
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.